These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9622114)

  • 21. Clinical predictors of defibrillation threshold in patients with implantable cardioverter-defibrillators.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Swiatecka G
    Kardiol Pol; 2005 Apr; 62(4):317-28; discussion 329-31. PubMed ID: 15928737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased Defibrillation Threshold and Minimized Myocardial Damage With Left Axilla Implantable Cardioverter Defibrillator Implantation.
    Noro M; Zhu X; Enomoto Y; Oikawa Y; Tatsunami H; Ishii R; Toyoda Y; Asami M; Sahara N; Takagi T; Narabayashi Y; Hashimoto H; Ito N; Kujime S; Sakai T; Nakamura K; Sakata T; Abe H; Sugi K
    Circ J; 2016; 80(4):878-86. PubMed ID: 26888267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Success of chronic defibrillation and the role of antiarrhythmic drugs with the automatic implantable cardioverter/defibrillator.
    Guarnieri T; Levine JH; Veltri EP; Griffith LS; Watkins L; Juanteguy J; Mower MM; Mirowski M
    Am J Cardiol; 1987 Nov; 60(13):1061-4. PubMed ID: 3673907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of biphasic shock duration on defibrillation threshold with different electrode configurations and phase 2 capacitances: prediction by upper-limit-of-vulnerability determination.
    Schauerte PN; Ziegert K; Waldmann M; Schöndube FA; Birkenhauer F; Mischke K; Grossmann M; Hanrath P; Stellbrink C
    Circulation; 1999 Mar; 99(11):1516-22. PubMed ID: 10086978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of shock polarity reversal on defibrillation threshold in an implantable cardioverter-defibrillator.
    Zienciuk A; Lubiński A; Królak T; Lewicka-Nowak E; Kempa M; Pazdyga A; Raczak G
    Kardiol Pol; 2007 May; 65(5):495-500; discussion 501-2. PubMed ID: 17577846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Estimation of defibrillation threshold using abdominally implanted cardioverter-defibrillator with an additional defibrillation pole in a dual-coil lead endocardial defibrillation system].
    Pazdyga A; Lubiński A; Lewicka-Nowak E; Królak T; Kempa M; Zienciuk A; Raczak G
    Pol Merkur Lekarski; 2007 Feb; 22(128):86-9. PubMed ID: 17598649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage.
    Schlüter T; Baum H; Plewan A; Neumeier D
    Clin Chem; 2001 Mar; 47(3):459-63. PubMed ID: 11238297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of defibrillation efficacy using implantable cardioverter-defibrillator with single- or dual-coil defibrillation leads and active can.
    Lubiński A; Lewicka-Nowak E; Zienciuk A; Królak T; Kempa M; Pazdyga A; Raczak G; Swiatecka G
    Kardiol Pol; 2005 Sep; 63(3):234-41; discussion 242-3. PubMed ID: 16180177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of cardiac compression on defibrillation efficacy and the upper limit of vulnerability.
    Idriss SF; Anstadt MP; Anstadt GL; Ideker RE
    J Cardiovasc Electrophysiol; 1995 May; 6(5):368-78. PubMed ID: 7551306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of upper limit of vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system.
    Souza JJ; Malkin RA; Ideker RE
    Circulation; 1995 Feb; 91(4):1247-52. PubMed ID: 7850965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cilostazol attenuates ventricular arrhythmia induction and improves defibrillation efficacy in swine.
    Kanlop N; Shinlapawittayatorn K; Sungnoon R; Weerateerangkul P; Chattipakorn S; Chattipakorn N
    Can J Physiol Pharmacol; 2010 Apr; 88(4):422-8. PubMed ID: 20555410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators.
    Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS
    J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of defibrillation testing on management during implantable cardioverter-defibrillator implantation.
    Leong-Sit P; Gula LJ; Diamantouros P; Krahn AD; Skanes AC; Yee R; Klein GJ
    Am Heart J; 2006 Dec; 152(6):1104-8. PubMed ID: 17161062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transthoracic defibrillation of short-lasting ventricular fibrillation: a randomised trial for comparison of the efficacy of low-energy biphasic rectilinear and monophasic damped sine shocks.
    Szili-Torok T; Theuns D; Verblaauw T; Scholten M; Kimman GJ; Res J; Jordaens L
    Acta Cardiol; 2002 Oct; 57(5):329-34. PubMed ID: 12405569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardioverter-defibrillator implantations without thoracotomy: clinical experience with various electrode configurations and defibrillation wave forms of an endocardial/subcutaneous defibrillator system].
    Neuzner J; Huth C; Friedl A; Reinisch P; Pitschner HF; Schlepper M
    Z Kardiol; 1993 Feb; 82(2):99-107. PubMed ID: 8465572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The zone of vulnerability to T wave shocks in humans.
    Swerdlow CD; Martin DJ; Kass RM; Davie S; Mandel WJ; Gang ES; Chen PS
    J Cardiovasc Electrophysiol; 1997 Feb; 8(2):145-54. PubMed ID: 9147699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Efficacy and Necessity of Routine Defibrillation Threshold Testing in Patients Undergoing Implantable Cardioverter-Defibrillator (ICD) Implantation.
    Ashino S; Nakai T; Sonoda K; Sasaki N; Kurokawa S; Ikeya Y; Okumura Y; Ohkubo K; Kunimoto S; Watanabe I; Hirayama A
    Int Heart J; 2015; 56(6):618-21. PubMed ID: 26549282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing ICD Test Shocks with a Simplified Upper Limit of Vulnerability.
    Pittaro M; Deforge W; Kroll MW
    Pacing Clin Electrophysiol; 2016 Jul; 39(7):652-7. PubMed ID: 27019321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of defibrillation threshold testing in the contemporary defibrillator patient population.
    Vischer AS; Sticherling C; Kühne MS; Osswald S; Schaer BA
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):437-41. PubMed ID: 23210803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.